Immunosuppression in Pancreas Transplantation  The Euro SPK Trials and Beyond

[en] The Immunosuppression in Pancreas Transplantation was historically based on the fact that the pancreas is an extremely immunogenic organ. Quadruple drug therapy with polyclonal or monoclonal antibodies induction was the mainstay therapy since the introduction of Cyclosporine A. In the modern era of Immunosuppression, Mycophenolate Mofetil replaced Azathioprine while Tacrolimus-another potent calcineurin inhibitor-had-and still has-a difficult challenge to replaced Cyclosporine A, due to its potential diabetogenic effect. Thanks to the first two EuroSPK studies which prospectively tried to answer several questions in that field. But, the future challenge will be in understanding the impact of innate immunity and ischemic reperfusion injuries on the long term graft function. Hopefully, new drugs will be available and tested to block unspecific deleterious reactions to attenuate the proinflammatory response. It will be the aim of the third Euro SPK Stud

Disciplines :

Surgery

Author, co-author :

Malaise, J.

De Roover, Arnaud ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation

Squifflet, Jean-Paul ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation

Land, W.

europe SPK study group

Language :

English

Title :

Immunosuppression in Pancreas Transplantation The Euro SPK Trials and Beyond

Publication date :

2008

Journal title :

Acta Chirurgica Belgica

ISSN :

1784-3421

eISSN :

2577-0160

Publisher :

Acta Medica Belgica, Bruxelles, Belgium

Volume :

108

Pages :

673-678

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 04 May 2009

Statistics

Number of views

38 (0 by ULiège)

Number of downloads

1 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

GRUESSNER A.C., SUTHERLAND D. E. R. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of October 2002. In: CECKA J. M., TERASAKI P. I. (eds.). Clinical Transplant. UCLA Immunogenetics Center, Los Angeles, CA, 2002, pp. 41-77.
WADSTROM J., BREKKE B., WRAMNER L., EKBERG H., TYDEN G. Triple versus Quadruple induction immunosuppression in pancreas transplantation. Transplant Proc, 1995, 27: 1317-1318.
CANTAROVICH D., KARAM G., GIRAL-C LASSE M., HOURMANT M., DANTAL J., BLANCHO G., LE NORMAND L., SOULILLOU J. P. Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation. Kidney Int, 1998, 54: 1351-1356.
LEFRANCOIS N. et al. Prophylactic polyclonal versus monoclonal antibodies in kidney and pancreas transplantation. Transplant Proc, 1990, 22: 632-633.
FASOLA C. G., HRICIK D. E., SCHULAK J. A. Combined pancreas-kidney transplants using quadruple immunosuppressive therapy: a comparison between antilymphoblast and antithymocyte globulins. Transplant Proc, 1995, 27: 3135-3136.
STRATTA R. J., TAYLOR R. J., WEIDE L. G., SINDHI R., SUDAN D., CASTALDO P., CUSHING K. A., FRISBIE K., RADIO S. J. A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplantation recipients. Transplant Proc, 1996, 28: 917-918.
KAUFMAN D. B., BURKE G., BRUCE D., SUTHERLAND D. E. R., JOHNSON C., GABER A. O., MERION R., SCHWEITZER E., MARSH C., ALFREY E., LEONE J., CONCEPION W., STEGALL M., GORES P., DANOVITCH G., TOLZMAN D., SCOTELLARO P., SALM K., KELLER A., FITZSIMMONS W. E. The role of antibody induction in simultaneous pancreas kidney transplant patients receiving tacrolimus + mycophenolate mofetil immunosuppression. Transplantation, 2000, 69: S 206.
KAUFMAN D. B., BURKE G. W. III, BRUCE D. S., JOHNSON C. P., GABER A. O., SUTHERLAND D. E. R., MERION R. M., GRUBER S. A., SCHWEITZER E., LEONE J. P., MARSH C. L., ALFREY E., CONCEPCION W., STEGALL M. D., SCHULAK J. A., GORES P. F., BENEDETTI E., SMITH C., HENNING A. K., KUEHNEL F., KING S., FITZSIMMONS W. E. A prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation. Am J Transplant, 2003, 3: 855-864.
FARNEY A., ROGERS J., ASHCROFT E., HARTMANN E., HART L., DOARES W., MOORE P., JARETT A., SUNDBERG A., ADAMS P., Stratta R. Alemtuzumab Versus Rabbit Antithymocyte Globulin Induction in Kidney and Pancreas Transplantation: A prospective Randomized Study. Am J Transplant, 2007, 7 (Suppl 2): 233 (330).
The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation, 1996, 61: 1029-1037.
MALAISE J., VAN OPHEM D., SQUIFFLET J. P. AND THE EUROSPK STUDY GROUP. Simultaneous Pancreas-Kidney Transplantation in the European Clinical setting: a comprehensive evaluation of long-term outcomes. Nephrol Dial Transplant, 2005, 20 (Suppl 2): ii1-ii62.
GRUESSNER R. W., SUTHERLAND D. E. R., DRANGSTVEIT M. B., TROPPMAN C., GRUESSNER A. C. Use of FK506 in pancreas transplantation. Transpl Int, 1996, 9 (Suppl 1): S 251-S 257.
BECHSTEIN W. O., MALAISE J., SAUDEK F. et al. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: 1-year results of a large multicentre trial. Transplantation, 2004, 77: 1221-1228.
PRATSCHKE J., MALAISE J., SAUDEK F., MARGREITER R., ARBOGAST H., FERNANDEZ-CRUZ L., PISARSKI P., VIEBAHN R., PEETERS P., NAKACHE R., BERNEY T., VANRENTERGHEM Y., BECHSTEIN W. AND THE EUROSPK STUDY GROUP. Sirolimus versus Mycophenolate Mofetil in Tacrolimus based primary simultaneous pancreas-kidney (SPK) Transplantation: 1 year results of a multicentre trial. Transplant Int, 2007, 20 (Suppl 1): S 270.
WULLSTEIN C., DROGNITZ O., WOESTE G., SCHARECK W. D. et al. High levels of C-reactive protein after simultaneous pancreas-kidney transplantation predict pancreas graft-related complications and graft survival. Transplantation, 2004 Jan 15, 77 (1): 60-4.
LAND W. Post ischemic reperfusion injury and allograft dysfunction: is allograft rejection the result of a fateful confusion by the immune system of danger and benefit? Transplant Proc, 1999 Feb-Mar, 31 (1-2): 332-6.
TORRAS J., CRUZADO J. M., GRINYO J. M. Ischemia and reperfusion injury in transplantation. Transplant Proc, 1999, 31 (6): 2217-8.
LAND W. G. The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. Transplantation, 2005 Mar 15, 79 (5): 505-14.
ALEGRE M. L., LEEMANS J., LE MOINE A., FLORQUIN S., DE WILDE V., CLONG A.., GOLDMAN M. The Multiple Facets of Toll-Like Receptors in Transplantation Biology. Transplantation, 2008, 86: 1-9.
AL-BAHRANI A. Z., AMMORI B. J. Clinical laboratory assessment of acute pancreatitis. Clin Chim Acta., 2005 Jul 15.
PINCEMAIL J., DEFRAIGNE J. O., DETRY O., FRANSSEN C. et al. Ischemia-reperfusion injury of rabbit kidney: comparative effects of desferrioxamine and N-Acetylcysteine as antioxidants. Transplant Proc, 2000 Mar, 32 (2): 475-6.
NAKANO H., NAGASAKI H., YOSHIDA K., KIGAWA G. et al. N-Acetylcysteine and anti-ICAM-1 monoclonal antibody reduce ischemia-reperfusion injury of the steatotic rat liver. Transplant Proc, 1998 Nov, 30 (7): 3763.
TAUT F. J. H., SCHMIDT H., ZAPLETAL C. M., THIES J. C. et al. N-Acetylcysteine induces shedding of selectins from liver and intestine during orthotopic liver transplantation. Clin Exp Immunol, 2001 May, 124 (2): 337-41.
MAYER H., THIES J., SCHMIDT J., GEBHARD M. M. et al. Decreasing reperfusion damage with NAcetylcysteine in experimental pancreas transplantation. Langenbecks Arch Chir Suppl Kongressbd, 1998, 115 (Suppl I): 147-51.
MAYER H., SCHMIDT J., THIES J., RYSCHICH E. et al. Characterization and reduction of ischemia/reperfusion injury after experimental pancreas transplantation. J Gastrointest Surg, 1999 Mar-Apr, 3 (2): 162-6.
HOFFMANN J. N., VOLLMAR B., INTHORN D., SCHILDBERG F. W. et al. Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway. Am J Physiol Cell Physiol, 2000 Jul, 279 (1): C98-C107.
MAKSAN S. M., GEBHARD M. M., MAKSAN M. O., HERFARTH C. et al. New aspects of anti-inflammatory potential of AT III: reduction of reperfusion injury after warm liver ischemia. Langenbecks Arch Chir Suppl Kongressbd, 1998, 115 (Suppl I): 383-5.
FERTMANN J. M., SAJZEWA E., ARBOGAST H. P., FRAUNBERGER P. et al. Effects of Antithrombin on cytokine secretion after human allogenic kidney transplantation. Transplantation, 2004 Jul 27, 78 (2): 222-3.
HACKERT T., WERNER J., UHL W., GEBHARD H. H. et al. Reduction of ischemia/reperfusion injury by Antithrombin III after experimental pancreas transplantation. Am J Surg, 2005 Jan, 189 (1): 92-7.
OSTROVSKY L., WOODMAN R. C., PAYNE D., TEOH D. et al. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation, 1997 Oct 7, 96 (7): 2302-10.
FERTMANN J., WIMMER C., ARBOGAST H., ILLNER W. D. et al. Single-shot Antithrombin application reduces reperfusion pancreatitis and prevents graft thrombosis in human simultaneous pancreas-kidney transplantation. Transplant International, 2005 Oct, 18 Suppl 2: 40.